Amgen data ‘muddies’ outlook for Cartesian, says Oppenheimer
Oppenheimer reiterates a Perform rating on Cartesian Therapeutics (RNAC) without a price target following the company’s Q4 report. The ...
Business Insider6d
Amgen data ‘muddies’ outlook for Cartesian, says Oppenheimer
Just today, Amgen (AMGN) announced updated Uplizna results showing a deepening of responses six months after a single repeat infusion, Opco points out. It believes extrapolating from Cartesian’s ...
pharmaphorum3d
A history of: Amgen
Amgen today is the biggest biotechnology company in the world, but its plush headquarters, global reach and tens of thousands of employees belie its humble origins. Founded in 1980 as Applied ...
Molecular Glues Market to Register Stunning Growth During the Forecast Period (2025-2034) | DelveInsight
DelveInsight's Molecular Glues Market Insights report includes a comprehensive understanding of current treatment practices, ...
CABLIVI Market Reports Positive Growth - Strong Momentum Expected to Continue | DelveInsight
DelveInsight's "CABLIVI Market Size, Forecast, and Market Insight Report" highlights the details around CABLIVI, a von ...
pharmaphorum2d
Amgen to acquire deCODE Genetics for US $415 million
Biotechnology company, Amgen, has announced that it has entered into a definitive agreement to acquire deCODE Genetics, a global leader in human genetics, for US $415 million. The all-cash ...
Cfr.org5d
American Pharmaceutical Companies Still Aren’t Paying Tax in the U.S.
Blog posts represent the views of CFR fellows and staff and not those of CFR, which takes no institutional positions. Most of the major U.S. pharmaceutical companies (AbbVie, Amgen, Bristol Myers ...
DelveInsight Business Research, LLP: CABLIVI Market Reports Positive Growth - Strong Momentum Expected to Continue | DelveInsight
Developed by Sanofi, CABLIVI is the first FDA-approved nanobody therapy for this condition. Increasing awareness, improved diagnostic rates, and rising demand for targeted therapies in hematology ...